866-997-4948(US-Canada Toll Free)

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 90 Pages

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome Pipeline Review, H1 2017, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 3, 2, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Respiratory Distress Syndrome - Overview
Acute Respiratory Distress Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acute Respiratory Distress Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
Altor BioScience Corp
Athersys Inc
Commence Bio Inc
Faron Pharmaceuticals Oy
GlaxoSmithKline Plc
Global Blood Therapeutics Inc
Hydra Biosciences Inc
Implicit Bioscience Ltd
Phylogica Ltd
Savara Inc
Silence Therapeutics Plc
Acute Respiratory Distress Syndrome - Drug Profiles
ALT-836 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-10901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-11006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBT-440 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2586881 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2862277 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HC-067047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon beta-1a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05285401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYC-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYC-36 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYC-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYC-98 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-1229 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acute Respiratory Distress Syndrome - Dormant Projects
Acute Respiratory Distress Syndrome - Discontinued Products
Acute Respiratory Distress Syndrome - Product Development Milestones
Featured News & Press Releases
Oct 31, 2016: New Patent Application Accepted by Finnish Patent Office Protect the intravenous use of interferon-beta in a novel formulation
Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial
Sep 03, 2016: Queens University Developing New Drug against Leading Causes of Death in the UK - Sepsis and Ards
May 25, 2016: First patient dosed in Savaras pivotal trial for PAP
Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation
Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS
Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome
Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP
Aug 09, 2015: Serendex to initiate first phase II clinical trial
Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November
May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced
May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceuticals inhalable biological drug for treatment of severe pulmonary diseases
May 10, 2015: Positive topline data from Serendex phase I clinical trial
Feb 27, 2015: Serendex submits phase I application
Feb 13, 2015: Serendex partners up with leading German lung center
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corp, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by Global Blood Therapeutics Inc, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by Phylogica Ltd, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H1 2017
Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H1 2017
Acute Respiratory Distress Syndrome - Dormant Projects, H1 2017
Acute Respiratory Distress Syndrome - Dormant Projects, H1 2017 (Contd..1), H1 2017
Acute Respiratory Distress Syndrome - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *